TVB-3166 | CAS#1533438-83-3 | FASN inhibitor

MedKoo Cat#: 525419 | Name: TVB-3166

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TVB-3166 is an orally-available, reversible, potent, and selective FASN inhibitor, inducing apoptosis, inhibiting anchorage-independent cell growth under lipid-rich conditions, and inhibiting in-vivo xenograft tumor growth.

Chemical Structure

TVB-3166

CAS#1533438-83-3

Theoretical Analysis

MedKoo Cat#: 525419

Name: TVB-3166

CAS#: 1533438-83-3

Chemical Formula: C24H24N4O

Exact Mass: 384.1950

Molecular Weight: 384.48

Elemental Analysis: C, 74.97; H, 6.29; N, 14.57; O, 4.16

Price and Availability

Size	Price	Availability
10mg	USD 350.00	2 Weeks
25mg	USD 650.00	2 Weeks
50mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

TVB-3166; TVB 3166; TVB3166;

IUPAC/Chemical Name

4-{1-[5-(4,5-Dimethyl-2H-pyrazol-3-yl)-2,4-dimethyl-benzoyl]-azetidin-3-yl}-benzonitrile

InChi Key

ICDQFUFDAFKCAX-UHFFFAOYSA-N

InChi Code

InChI=1S/C24H24N4O/c1-14-9-15(2)22(10-21(14)23-16(3)17(4)26-27-23)24(29)28-12-20(13-28)19-7-5-18(11-25)6-8-19/h5-10,20H,12-13H2,1-4H3,(H,26,27)

SMILES Code

N#CC1=CC=C(C2CN(C(C3=CC(C4=C(C)C(C)=NN4)=C(C)C=C3C)=O)C2)C=C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	DMSO	5.0	13.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 384.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Mukha D, Dessain J, O'Connor S, Pniewski K, Bertolazzi F, Patel J, Mullins M, Schug ZT. Identification of Fasnall as a therapeutically effective Complex I inhibitor. bioRxiv [Preprint]. 2024 May 6:2024.05.03.592013. doi: 10.1101/2024.05.03.592013. PMID: 38766222; PMCID: PMC11100613. 2: Aquino IG, Cuadra-Zelaya FJM, Bizeli ALV, Palma PVB, Mariano FV, Salo T, Coletta RD, Bastos DC, Graner E. Isolation and phenotypic characterization of cancer stem cells from metastatic oral cancer cells. Oral Dis. 2024 Nov;30(8):4886-4897. doi: 10.1111/odi.15003. Epub 2024 May 20. PMID: 38764396. 3: Zhou L, Du K, Dai Y, Zeng Y, Luo Y, Ren M, Pan W, Liu Y, Zhang L, Zhu R, Feng D, Tian F, Gu C. Metabolic reprogramming based on RNA sequencing of gemcitabine- resistant cells reveals the FASN gene as a therapeutic for bladder cancer. J Transl Med. 2024 Jan 13;22(1):55. doi: 10.1186/s12967-024-04867-8. PMID: 38218866; PMCID: PMC10787972. 4: Souchek JJ, Laliwala A, Houser L, Muraskin L, Vu Q, Mohs AM. Fatty Acid Synthase Inhibitors Enhance Microtubule-Stabilizing and Microtubule- Destabilizing Drugs in Taxane-Resistant Prostate Cancer Cells. ACS Pharmacol Transl Sci. 2023 Nov 6;6(12):1859-1869. doi: 10.1021/acsptsci.3c00182. PMID: 38093839; PMCID: PMC10714433. 5: O'Farrell M, Duke G, Crowley R, Buckley D, Martins EB, Bhattacharya D, Friedman SL, Kemble G. FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models. Sci Rep. 2022 Sep 19;12(1):15661. doi: 10.1038/s41598-022-19459-z. PMID: 36123383; PMCID: PMC9485253. 6: McClellan B, Pham T, Harlow B, Lee G, Quach D, Jolly C, Brenner A, deGraffenried L. Modulation of Breast Cancer Cell FASN Expression by Obesity- Related Systemic Factors. Breast Cancer (Auckl). 2022 Aug 22;16:11782234221111374. doi: 10.1177/11782234221111374. PMID: 36035625; PMCID: PMC9400406. 7: Mekhail K, Lee M, Sugiyama M, Astori A, St-Germain J, Latreille E, Khosraviani N, Wei K, Li Z, Rini J, Lee WL, Antonescu C, Raught B, Fairn GD. FASN inhibitor TVB-3166 prevents S-acylation of the spike protein of human coronaviruses. J Lipid Res. 2022 Sep;63(9):100256. doi: 10.1016/j.jlr.2022.100256. Epub 2022 Jul 31. PMID: 35921881; PMCID: PMC9339154. 8: Aliyari SR, Ghaffari AA, Pernet O, Parvatiyar K, Wang Y, Gerami H, Tong AJ, Vergnes L, Takallou A, Zhang A, Wei X, Chilin LD, Wu Y, Semenkovich CF, Reue K, Smale ST, Lee B, Cheng G. Suppressing fatty acid synthase by type I interferon and chemical inhibitors as a broad spectrum anti-viral strategy against SARS- CoV-2. Acta Pharm Sin B. 2022 Apr;12(4):1624-1635. doi: 10.1016/j.apsb.2022.02.019. Epub 2022 Feb 28. PMID: 35251918; PMCID: PMC8883762. 9: Gruslova A, McClellan B, Balinda HU, Viswanadhapalli S, Alers V, Sareddy GR, Huang T, Garcia M, deGraffenried L, Vadlamudi RK, Brenner AJ. FASN inhibition as a potential treatment for endocrine-resistant breast cancer. Breast Cancer Res Treat. 2021 Jun;187(2):375-386. doi: 10.1007/s10549-021-06231-6. Epub 2021 Apr 24. PMID: 33893909. 10: Oh JE, Jung BH, Park J, Kang S, Lee H. Deciphering Fatty Acid Synthase Inhibition-Triggered Metabolic Flexibility in Prostate Cancer Cells through Untargeted Metabolomics. Cells. 2020 Nov 10;9(11):2447. doi: 10.3390/cells9112447. PMID: 33182594; PMCID: PMC7697567. 11: Rae C, Fragkoulis GI, Chalmers AJ. Cytotoxicity and Radiosensitizing Activity of the Fatty Acid Synthase Inhibitor C75 Is Enhanced by Blocking Fatty Acid Uptake in Prostate Cancer Cells. Adv Radiat Oncol. 2020 Jun 29;5(5):994-1005. doi: 10.1016/j.adro.2020.06.022. PMID: 33083663; PMCID: PMC7557210. 12: Aquino IG, Bastos DC, Cuadra-Zelaya FJM, Teixeira IF, Salo T, Coletta RD, Graner E. Anticancer properties of the fatty acid synthase inhibitor TVB-3166 on oral squamous cell carcinoma cell lines. Arch Oral Biol. 2020 May;113:104707. doi: 10.1016/j.archoralbio.2020.104707. Epub 2020 Mar 10. PMID: 32197133. 13: Tao T, Su Q, Xu S, Deng J, Zhou S, Zhuang Y, Huang Y, He C, He S, Peng M, Hocher B, Yang X. Down-regulation of PKM2 decreases FASN expression in bladder cancer cells through AKT/mTOR/SREBP-1c axis. J Cell Physiol. 2019 Mar;234(3):3088-3104. doi: 10.1002/jcp.27129. Epub 2018 Sep 17. PMID: 30221356. 14: Heuer TS, Ventura R, Mordec K, Lai J, Fridlib M, Buckley D, Kemble G. FASN Inhibition and Taxane Treatment Combine to Enhance Anti-tumor Efficacy in Diverse Xenograft Tumor Models through Disruption of Tubulin Palmitoylation and Microtubule Organization and FASN Inhibition-Mediated Effects on Oncogenic Signaling and Gene Expression. EBioMedicine. 2017 Feb;16:51-62. doi: 10.1016/j.ebiom.2016.12.012. Epub 2016 Dec 24. PMID: 28159572; PMCID: PMC5474427. 15: Ohol YM, Wang Z, Kemble G, Duke G. Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Syncytial Virus and Other Respiratory Viruses. PLoS One. 2015 Dec 11;10(12):e0144648. doi: 10.1371/journal.pone.0144648. PMID: 26659560; PMCID: PMC4684246. 16: Ventura R, Mordec K, Waszczuk J, Wang Z, Lai J, Fridlib M, Buckley D, Kemble G, Heuer TS. Inhibition of de novo Palmitate Synthesis by Fatty Acid Synthase Induces Apoptosis in Tumor Cells by Remodeling Cell Membranes, Inhibiting Signaling Pathways, and Reprogramming Gene Expression. EBioMedicine. 2015 Jul 2;2(8):808-24. doi: 10.1016/j.ebiom.2015.06.020. PMID: 26425687; PMCID: PMC4563160.